PUBLISHER: The Business Research Company | PRODUCT CODE: 1619482
PUBLISHER: The Business Research Company | PRODUCT CODE: 1619482
Cardiac marker testing involves a series of diagnostic tests designed to measure specific substances in the blood that signal damage or stress to the heart. These markers, often proteins or enzymes, are released into the bloodstream when the heart muscle is injured. Cardiac marker tests are vital for diagnosing and assessing conditions such as myocardial infarction (heart attack), heart failure, and other heart-related diseases.
The primary products used in cardiac marker testing include reagents, kits, and instruments. Reagents and kits are crucial components in these tests, containing the necessary chemicals and materials for conducting diagnostics. They provide various biomarkers, such as troponin I and T, creatine kinase-MB (CK-MB), natriuretic peptide, myoglobin, high-sensitivity C-reactive protein, and others, and are utilized in laboratory testing facilities, point-of-care testing facilities, and academic institutions.
The cardiac marker testing market research report is one of a series of new reports from The Business Research Company that provides cardiac marker testing market statistics, including cardiac marker testing industry global market size, regional shares, competitors with a cardiac marker testing market share, detailed cardiac marker testing market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac marker testing industry. This cardiac marker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cardiac marker testing market size has grown rapidly in recent years. It will grow from $5.92 billion in 2023 to $6.52 billion in 2024 at a compound annual growth rate (CAGR) of 10%. The growth during the historical period can be attributed to the increase in the geriatric population, the rise in educational campaigns, growing awareness, the expansion of healthcare infrastructure, and the increasing patient population.
The cardiac marker testing market size is expected to see rapid growth in the next few years. It will grow to $9.35 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth during the forecast period can be attributed to the rising incidence of cardiovascular diseases, increasing strategic collaborations and partnerships, expanding research and development initiatives, favorable reimbursement policies, and growing demand for point-of-care (POC) testing. Key trends anticipated in the forecast period include advancements in diagnostic technologies, the use of automated analyzers, the development of advanced cardiac marker testing assays, the integration of digital health technologies, and the emergence of integrative technologies.
The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the cardiac marker testing market in the coming years. Cardiovascular diseases (CVDs), encompassing conditions such as coronary artery disease, heart failure, and stroke, affect the heart and blood vessels. Factors such as unhealthy diets, lack of physical activity, tobacco use, excessive alcohol consumption, and air pollution contribute to the rise in CVD cases. Cardiac marker testing plays a crucial role in diagnosing cardiovascular diseases, assessing their severity, and monitoring treatment progress by detecting specific biomarkers released during myocardial injury. For instance, the American Heart Association reported in January 2024 that the age-adjusted death rate from cardiovascular disease increased by 4.0%, from 224.4 per 100,000 in 2023 to 233.3 per 100,000. Additionally, sudden cardiac arrest accounted for 20,114 deaths in the U.S. in 2021. As a result, the growing incidence of cardiovascular diseases is fueling the demand for cardiac marker testing.
Leading companies in the cardiac marker testing market are focusing on the development of advanced products, such as cardiac assays, to provide accurate and valuable information regarding heart health and function. These assays are diagnostic tests designed to measure biomarkers or other indicators in blood or other samples, helping to assess heart function, diagnose cardiovascular diseases, and evaluate the risk of heart-related conditions. For example, in October 2023, Mindray, a medical device company based in China, introduced the troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTnI assay is notable for its high sensitivity, precision, and reliability, surpassing the minimum requirements by achieving a 93% detection rate between the limit of detection (LoD) and the 99th percentile upper reference limit (URL), and maintaining an imprecision coefficient of variation (CV) below 5% at the 99th URL. This makes it highly effective in detecting myocardial injury. Mindray's NT-proBNP assay is a key cardiac marker for heart failure, offering high precision with a CV of <=5% and minimizing interference from 55 common heart disease medications, ensuring accurate detection and management of heart failure.
In August 2024, VION Biosciences, a US-based life sciences platform, acquired Ansh Labs for an undisclosed amount. This acquisition is intended to bolster VION Biosciences' presence in the diagnostic sector, integrate advanced technologies, and expand its product offerings in immunoassay development. Ansh Labs is a US-based biotechnology company.
Major companies operating in the cardiac marker testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Tosoh Corporation, bioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., Guangzhou Wondfo Biotech Co. Ltd., Randox laboratories Ltd., Getein Biotech Inc., Fujirebio Inc., Mayo Clinic Laboratories, Kainos Medicine Inc., Alere Inc., Nano-Ditech Corporation, 1Drop Diagnostics
North America was the largest region in the cardiac marker testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac marker testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cardiac marker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cardiac marker testing market consists of revenues earned by entities by providing services such as homocysteine testing, cardiac stress testing, genetic testing for cardiovascular risk, remote monitoring and telemedicine services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac marker testing market also includes sales of lipoprotein(a) test kits, cardiac biomarker panels, point-of-care testing devices and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cardiac Marker Testing Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cardiac marker testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cardiac marker testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiac marker testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.